Cargando…
Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease
BACKGROUND: Cognitive decline has been reported in premanifest and manifest Huntington’s disease but reliable biomarkers are lacking. Inner retinal layer thickness seems to be a good biomarker of cognition in other neurodegenerative diseases. OBJECTIVE: To explore the relationship between optical co...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345164/ https://www.ncbi.nlm.nih.gov/pubmed/37079031 http://dx.doi.org/10.1007/s00415-023-11720-3 |
_version_ | 1785073025343815680 |
---|---|
author | Murueta-Goyena, Ane Del Pino, Rocío Acera, Marian Teijeira-Portas, Sara Romero, David Ayala, Unai Fernández-Valle, Tamara Tijero, Beatriz Gabilondo, Iñigo Gómez Esteban, Juan Carlos |
author_facet | Murueta-Goyena, Ane Del Pino, Rocío Acera, Marian Teijeira-Portas, Sara Romero, David Ayala, Unai Fernández-Valle, Tamara Tijero, Beatriz Gabilondo, Iñigo Gómez Esteban, Juan Carlos |
author_sort | Murueta-Goyena, Ane |
collection | PubMed |
description | BACKGROUND: Cognitive decline has been reported in premanifest and manifest Huntington’s disease but reliable biomarkers are lacking. Inner retinal layer thickness seems to be a good biomarker of cognition in other neurodegenerative diseases. OBJECTIVE: To explore the relationship between optical coherence tomography-derived metrics and global cognition in Huntington’s Disease. METHODS: Thirty-six patients with Huntington’s disease (16 premanifest and 20 manifest) and 36 controls matched by age, sex, smoking status, and hypertension status underwent macular volumetric and peripapillary optical coherence tomography scans. Disease duration, motor status, global cognition and CAG repeats were recorded in patients. Group differences in imaging parameters and their association with clinical outcomes were analyzed using linear mixed-effect models. RESULTS: Premanifest and manifest Huntington’s disease patients presented thinner retinal external limiting membrane-Bruch’s membrane complex, and manifest patients had thinner temporal peripapillary retinal nerve fiber layer compared to controls. In manifest Huntington’s disease, macular thickness was significantly associated with MoCA scores, inner nuclear layer showing the largest regression coefficients. This relationship was consistent after adjusting for age, sex, and education and p-value correction with False Discovery Rate. None of the retinal variables were related to Unified Huntington’s Disease Rating Scale score, disease duration, or disease burden. Premanifest patients did not show a significant association between OCT-derived parameters and clinical outcomes in corrected models. CONCLUSIONS: In line with other neurodegenerative diseases, OCT is a potential biomarker of cognitive status in manifest HD. Future prospective studies are needed to evaluate OCT as a potential surrogate marker of cognitive decline in HD. |
format | Online Article Text |
id | pubmed-10345164 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-103451642023-07-15 Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease Murueta-Goyena, Ane Del Pino, Rocío Acera, Marian Teijeira-Portas, Sara Romero, David Ayala, Unai Fernández-Valle, Tamara Tijero, Beatriz Gabilondo, Iñigo Gómez Esteban, Juan Carlos J Neurol Original Communication BACKGROUND: Cognitive decline has been reported in premanifest and manifest Huntington’s disease but reliable biomarkers are lacking. Inner retinal layer thickness seems to be a good biomarker of cognition in other neurodegenerative diseases. OBJECTIVE: To explore the relationship between optical coherence tomography-derived metrics and global cognition in Huntington’s Disease. METHODS: Thirty-six patients with Huntington’s disease (16 premanifest and 20 manifest) and 36 controls matched by age, sex, smoking status, and hypertension status underwent macular volumetric and peripapillary optical coherence tomography scans. Disease duration, motor status, global cognition and CAG repeats were recorded in patients. Group differences in imaging parameters and their association with clinical outcomes were analyzed using linear mixed-effect models. RESULTS: Premanifest and manifest Huntington’s disease patients presented thinner retinal external limiting membrane-Bruch’s membrane complex, and manifest patients had thinner temporal peripapillary retinal nerve fiber layer compared to controls. In manifest Huntington’s disease, macular thickness was significantly associated with MoCA scores, inner nuclear layer showing the largest regression coefficients. This relationship was consistent after adjusting for age, sex, and education and p-value correction with False Discovery Rate. None of the retinal variables were related to Unified Huntington’s Disease Rating Scale score, disease duration, or disease burden. Premanifest patients did not show a significant association between OCT-derived parameters and clinical outcomes in corrected models. CONCLUSIONS: In line with other neurodegenerative diseases, OCT is a potential biomarker of cognitive status in manifest HD. Future prospective studies are needed to evaluate OCT as a potential surrogate marker of cognitive decline in HD. Springer Berlin Heidelberg 2023-04-20 2023 /pmc/articles/PMC10345164/ /pubmed/37079031 http://dx.doi.org/10.1007/s00415-023-11720-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Communication Murueta-Goyena, Ane Del Pino, Rocío Acera, Marian Teijeira-Portas, Sara Romero, David Ayala, Unai Fernández-Valle, Tamara Tijero, Beatriz Gabilondo, Iñigo Gómez Esteban, Juan Carlos Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease |
title | Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease |
title_full | Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease |
title_fullStr | Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease |
title_full_unstemmed | Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease |
title_short | Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease |
title_sort | retinal thickness as a biomarker of cognitive impairment in manifest huntington’s disease |
topic | Original Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345164/ https://www.ncbi.nlm.nih.gov/pubmed/37079031 http://dx.doi.org/10.1007/s00415-023-11720-3 |
work_keys_str_mv | AT muruetagoyenaane retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT delpinorocio retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT aceramarian retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT teijeiraportassara retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT romerodavid retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT ayalaunai retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT fernandezvalletamara retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT tijerobeatriz retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT gabilondoinigo retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease AT gomezestebanjuancarlos retinalthicknessasabiomarkerofcognitiveimpairmentinmanifesthuntingtonsdisease |